San Francisco, California, October 31, 2017 : The awareness pertaining to the prevalence of hypogonadism and the availability of treatment options will ensure a prosperous future for the global male hypogonadism market, according to a recent commerce and business study by TMR Research. The report, titled “Male Hypogonadism Market – Global Industry Analysis, Size, Share, Trends, Analysis, Growth, and Forecast 2017 – 2025,” aspires to serve as a credible business tool for targeted audiences such as medical equipment manufacturers, research institutes, and government agencies. Beginning with an overview of the current scenario of the global hypogonadism market, the report provides in-depth analysis of all market dynamics such as trends, drivers, and restraints, segments it on the basis of therapy, drug delivery more, and product type, takes stock of the potential demand that can be expected from various regions, and finishes off with a detailed section on the competitive landscape, which includes profiles of a number of leading companies of this market and their position in terms of shares.
As per the findings of the report, the demand in the global male hypogonadism market will expand at a notable CAGR during the forecast period of 2017 to 2025, which would be primarily a reflection of escalating geriatric population who are at high risk of hypogonadism, changing lifestyle, escalation in infertility rate, and increasing awareness level among the urban population owing to government initiatives and ubiquity of smartphones and social media. On the other hand, cautions and warning issued by the FDA and social taboos are hindering the growth of this market.
The report notes that male hypogonadism, which is clinical condition wherein enough testosterone is not produced, leads to impaired growth of body hair, reduced development of muscle mass, and origination of breast tissues. In the recent past, the male hypogonadism market has gained momentum from the prevalence & incidences of men with testosterone deficiency. In addition to that, the risk of hypogonadism is extremely high among the geriatrics as well as in the population suffering from diabetes or obesity, which are often a result of restless lifestyle and ill eating habits of urban population. These factors will keep the market for male hypogonadism in good stead in the near future. On the other hand, high rate of side effects caused by testosterone products are anticipated to obstruct the growth of the testosterone replacement therapy (TRT) segment in this market. Nevertheless, the vendors operating in this market will gain new opportunities from recent technological advancements during the forecast period.
Based on therapy, the market for male hypogonadism can be segmented into LH, hCG, FSH, and GnRH, whereas on the basis of drug delivery, the market can be bifurcated into topical gels, injectables, transdermal patches, and others. Product-wise, the global male hypogonadism market can be classified into klinefelters syndrome, pituitary disorders, kallmann syndrome, and others. Geographically, the report takes stock of the potential of every important region and country, such as North America including the U.S. and Canada, Asia Pacific including China, India, and Japan, and Europe including the U.K., France, Germany, and Italy. For each of these regions and country, the report provides key growth factors and opportunities, explores the recent trends, and evaluates the size of the market besides offering the forecasts.
As far as the competitive landscape is concerned, Bayer AG., Allergan plc, AbbVie Inc., Astrazeneca plc, Eli Lilly and Company Ltd., Merck & Co., Inc., Ferring, Endo International plc, Finox Biotech, Laboratoires Genevrier, Teva Pharmaceutical Industries Ltd., and IBSA Institut Biochimque SA are some of the key companies operating in the global male hypogonadism market. Most of these players have adopted product approval as their primary strategy to meet the changing demand and stay ahead of the curve.
Get Sample Brochure of this Report Study